Released March 11, 2021 | BEIJING, CHINA
en
WuXi Biologics has authorized Exelixis exclusively to expand its oncology biological drug production. WuXi AppTec, which includes WuXi Biologics, has 14 plants, with half in the U.S. and half in China.
WuXi AppTec has invested more than $707.4 million in China to construct or upgrade four plants since 2020.
Click here for a list of related projects, and see graph below showing the investment by state.
WuXi AppTec has invested more than $707.4 million in China to construct or upgrade four plants since 2020.
Click here for a list of related projects, and see graph below showing the investment by state.
